Mitropoulos Konstantinos, Johnson Lindsey, Vozikis Athanassios, Patrinos George P
Golden Helix Institute of Biomedical Research, Athens, Greece.
Drug Metabol Drug Interact. 2011;26(4):143-6. doi: 10.1515/DMDI.2011.028. Epub 2011 Oct 21.
Pharmacogenomics holds promise of personalized treatment for patients suffering from many common diseases, particularly those with multiple treatment modalities. Owing to recent advances in the deciphering of the human genome sequence, high throughput genotyping technology has led to the reduction of the overall costs of genetic testing and allowed the inclusion of genotype-related dosing recommendations into drug package inserts, hence enabling the integration of pharmacogenomics into clinical practice. Although pharmacogenomics gradually assumes an important part in routine clinical practice in developed countries, many countries, particularly from the developing world, still do not have access either to the knowledge or the resources to individualize drug therapy. The PharmacoGenetics for Every Nation Initiative (PGENI) aims to fill this gap, by making pharmacogenomics globally applicable, not only by defining population-specific pharmacogenomic marker frequency profiles but also by formulating country-specific recommendations for drug efficacy and safety. This article aims to highlight the PGENI activities in Europe in an effort to make pharmacogenomics readily applicable in the European healthcare systems, particularly those in developing countries.
药物基因组学有望为患有多种常见疾病的患者提供个性化治疗，尤其是那些有多种治疗方式的疾病。由于人类基因组序列破译方面的最新进展，高通量基因分型技术降低了基因检测的总体成本，并使与基因型相关的给药建议能够纳入药品说明书，从而使药物基因组学能够融入临床实践。尽管药物基因组学在发达国家的常规临床实践中逐渐占据重要地位，但许多国家，尤其是发展中国家，仍然无法获得个性化药物治疗所需的知识或资源。“全球药物遗传学倡议”（PGENI）旨在填补这一空白，通过使药物基因组学在全球范围内适用，不仅要确定特定人群的药物基因组标志物频率概况，还要制定针对各国的药物疗效和安全性建议。本文旨在重点介绍PGENI在欧洲的活动，以使药物基因组学能够在欧洲医疗系统，特别是发展中国家的医疗系统中易于应用。
